Skip to main content
TipRanks
Go Ultimate75% OFF

Pharming Group (PHG) AI Stock Analysis

0 Followers
DE:PHG

Pharming Group

(Frankfurt:PHG)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Pediatric regulatory expansionThe U.K. pediatric approval expands Joenja’s authorized population and strengthens Pharming’s position in targeted rare-disease treatment. Broader eligibility can support additional patient identification, international commercialization, and recurring therapy revenue over the coming quarters.
Negative Factors
Unresolved CEO transitionAn unresolved leadership transition can create execution and strategic continuity risk while Pharming is commercializing Joenja and advancing multiple clinical programs. Interim leadership may also delay major decisions or reduce clarity around long-term priorities.

Pharming Group (PHG) vs. iShares MSCI Germany ETF (EWG)

-40%-20%0%20%40%60%DE:PHG+2.75%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 891.80M
Dividend Yield
―
Average Volume (3M)
275
Price to Earnings (P/E)
35.7
Beta (1Y)
0.71
Revenue Growth
1.73%
EPS Growth
―
Country
Germany
Employees
407
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Pharming Group Business Overview & Revenue Model

Company Description

Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical need...

Pharming Group Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:6.67%|Next Earnings Date:Mar 18, 2027
Earnings Call SentimentPositive

The call was predominantly positive, supported by 21% third-quarter revenue growth, 58% Joenja growth, RUCONEST's return to revenue growth and stabilized U.S. demand, an 89% increase in operating profit, improved full-year guidance, strong liquidity, pediatric and international expansion, and encouraging clinical progress. The main challenges were the expected approximately 3% full-year decline in RUCONEST U.S. revenue, inventory-related timing effects, manufacturing inventory impairments, the unresolved CEO search, and prior FALCON site-activation delays.

Positive Updates

Strong Third-Quarter Revenue Growth
Third-quarter revenue was $117.6 million, up 21% year over year and ahead of market expectations. Both commercial products contributed to growth.

Negative Updates

RUCONEST Full-Year U.S. Revenue Expected to Decline
At the midpoint of full-year guidance, RUCONEST U.S. revenue is expected to decline approximately 3% for 2026. The full-year outlook assumes stabilization and a return to growth in the second half of the year.

Company Guidance

For the full year 2026, revenue guidance was tightened to $380 million to $390 million, representing 14% growth, while operating expense guidance was lowered to $310 million to $315 million, representing 0% to 1% growth, including approximately $35 million incremental R&D investment and about $9 million of structural G&A savings; guidance assumes RUCONEST revenue will stabilize and return to growth in the second half of 26 and Joenja will deliver significant and accelerating growth, with RUCONEST U. S. Revenue expected to decline approximately 3% for the full year and Joenja annual revenue growth expected in the mid-30s%, while cost of goods sold is expected to be approximately 12% of revenue, corresponding to a gross margin of 88%, and Q4 revenue is implied to be roughly $100 million to $110 million; the company expects an initial bolus of new Joenja pediatric patients on therapy throughout Q4 in the range of 15 to 20 patients, expects 145 of the planned 180 FALCON participants to be enrolled by the end of this year, enrollment to be complete during the first half of 27, and top line results approximately 1 year after enrollment is complete, and expects to report top-line CVID results in November.

Pharming Group Risk Analysis

Pharming Group disclosed 63 risk factors in its most recent earnings report. Pharming Group reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.Joenja is a newly approved drug in the U.S. and could develop unexpected safety or efficacy concerns, which would likely have a material adverse effect on us.Q4, 2023

Pharming Group Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:PHG against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PLXPLX77Outperform$257.17M11.7230.74%―36.96%266.67%
RIGLRIGL73Outperform$837.18M2.6473.94%―2.18%165.65%
ZVRAZVRA73Outperform$540.30M7.0938.19%―75.10%103.22%
FENCFENC66Neutral$410.25M507.424.92%―71.09%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
XFORXFOR43Neutral$318.59M-4.66-49.62%―-50.08%93.36%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%DE:PHGPLXRIGLZVRAFENCXFORDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:PHG and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:PHGPharming Group Nv11.200.302.75%
PLXProtalix Biotherapeutics3.051.1661.38%
RIGLRigel Pharmaceuticals44.461.954.59%
ZVRAZevra Therapeutics, Inc.9.08-0.10-1.09%
FENCFennec Pharmaceuticals11.622.8732.80%
XFORX4 Pharmaceuticals3.12-0.54-14.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.